IngredientsCatecholamines are a class of biologically active molecules that function as both neurotransmitters and hormones. Catecholamines are defined as low molecular weight compounds composed of a catechol nucleus and an amine-containing side chain, including substances such as dopamine, norepinephrine, and epinephrine, which play significant roles in neural and endocrine functions. More precisely, catecholamines are characterized by a catechol group (a benzene ring with two hydroxyl groups) to which is attached an amine (nitrogen-containing) group.
The three physiologically active catecholamines found in humans are:
Catecholamines are monoamine neurotransmitters and circulating hormones derived from the amino acid tyrosine, produced by the sympathetic nervous system, brain, and adrenal medulla. The three physiologically active catecholamines synthesized in the human body are epinephrine (adrenaline), norepinephrine (noradrenaline), and dopamine.
Catecholamines are a class of neurotransmitters that are found within the larger class of neurotransmitters, biogenic amines. The catecholamines share many characteristics. Catecholamines have a half-life of a few minutes when circulating in the blood.
All catecholamines are synthesized from the amino acid l-tyrosine according to the following sequence: tyrosine → dopa (dihydroxyphenylalanine) → dopamine → norepinephrine (noradrenaline) → epinephrine (adrenaline).
In the body, catecholamines are produced mainly by the chromaffin cells of the adrenal medulla and the postganglionic fibers of the sympathetic nervous system. Dopamine, which acts as a neurotransmitter in the central nervous system, is largely produced in neuronal cell bodies in two areas of the brainstem: the ventral tegmental area and the substantia nigra, the latter of which contains neuromelanin-pigmented neurons. The similarly neuromelanin-pigmented cell bodies of the locus coeruleus produce norepinephrine.
In nutritional and supplement contexts, catecholamines themselves are not ingested directly — the body synthesizes them endogenously from dietary amino acid precursors. The synthesis of catecholamines relies heavily on the amino acid tyrosine, which is abundant in protein-rich foods like meat, dairy, and legumes. Those richest in tyrosine include dairy, eggs, beans, fish, and meat such as beef and chicken. The only prominent botanical that delivers a direct catecholamine-pathway intermediate is Mucuna pruriens (velvet bean), whose seeds contain substantial concentrations of L-DOPA (levodopa), the immediate biosynthetic precursor to dopamine.
In the dietary supplement market, catecholamine support is approached through several types of preparations:
Importantly, catecholamine (unspecified) as a direct nutritional ingredient lacks substantial clinical validation. Most supplement research therefore focuses not on catecholamines themselves but on precursors such as tyrosine and L-DOPA from Mucuna pruriens.
Adrenaline, the prototype, was discovered in the adrenals in 1893/1894. The formal biochemical history of catecholamines as a recognized chemical class spans the early twentieth century. The isolation of adrenaline was accomplished by two prominent figures, John Jacob Abel and Jokichi Takamine, between 1897 and 1901, marking a major milestone in biochemistry and endocrinology. In 1897, John Jacob Abel in Baltimore partially purified adrenal extracts to what he called "epinephrin." The Japanese chemist Jōkichi Takamine, who had set up his own laboratory in New York, invented an isolation procedure and obtained it in pure crystal form in 1901, and arranged for Parke-Davis to market it as "Adrenalin."
Medical historians give Takamine and Aldrich the credit for one of medical history's most important scientific feats, the first identification of a hormone. In 1904, Friedrich Stolz synthesized EPI entirely chemically, so that EPI was also the first hormone to be produced artificially in a laboratory.
In 1903, natural adrenaline was found to be optically active and levorotary. In 1905 synthesis of the racemate was achieved by Friedrich Stolz at Hoechst AG in Höchst (Frankfurt am Main) and by Henry Drysdale Dakin at the University of Leeds. In 1939, dopa decarboxylase was the first enzyme in the biosynthesis of catecholamines to be described. Later other catecholamines like noradrenaline and dopamine were characterized. It took until 1948 before the existence of at least two different receptors for the different effects was accepted.
On April 16, 1945, Ulf von Euler of Karolinska Institute in Stockholm submitted to Nature the first of a series of papers that gave proof that noradrenaline was the transmitter of the sympathetic nervous system. Von Euler won the Nobel Prize in 1970 for his work on noradrenaline.
While catecholamines as a chemical class were not known to ancient cultures, the botanical source of L-DOPA — Mucuna pruriens (velvet bean, cowhage) — has an extensive traditional history. Mucuna pruriens (MP), or velvet bean, has been used as an alternative medicine in India for over 4500 years, predominantly due to the natural abundance of the non-protein amino acid L-3,4-dihydroxyphenylalanine (L-DOPA).
The seed powder of the leguminous plant, Mucuna pruriens, has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. In classical Ayurvedic texts, the condition now identified as Parkinson's disease is described as Kampavata. In Ayurveda, PD is closely correlated with Kampavata, a Vata-dominant neurodegenerative condition caused by Kapha-avaranajanya Vata prakopa.
This legume, native to the tropical regions of India, Africa and the West Indies, and also known as velvet bean, has been used in Ayurveda medicine since 1500 B.C. The ancients used Mucuna pruriens to treat things like snakebite, intestinal problems, sexual issues, and a melancholy mood.
The use of adrenal gland extracts in a proto-pharmacological sense also predates formal biochemical understanding: By 1895 physicians began experimenting with adrenal extracts. In 1893, George Oliver (1841–1915), using his own instruments, studied the impact of glycerol extracts on arteries. Doctors were quick to start prescribing epinephrine for their asthmatics. Yet the majority of asthmatics continued to stick with their usual asthma remedies, which mainly consisted of asthma cigarettes, powders and incense.
The prominence of catecholamines and their congeners in allergic diseases rests chiefly on their use in asthma and acute hypersensitivity reactions, such as anaphylaxis. They act in these indications by activating both α- and β-adrenoceptors.
Dopamine (DA): Dopamine is primarily synthesized in the brain, particularly in areas such as the substantia nigra and ventral tegmental area, where it functions mainly as a neurotransmitter. Dopamine, a catecholamine transmitter, plays many roles in the nervous system, but it is best known for its roles in reward and movement.
Norepinephrine (NE / Noradrenaline): Norepinephrine is also the transmitter used by the locus coeruleus, a brainstem nucleus that projects diffusely to a variety of forebrain targets, where it influences sleep and wakefulness, attention, and feeding behavior. The most prominent class of neurons that synthesize norepinephrine is sympathetic ganglion cells, since norepinephrine is the major peripheral transmitter in this division of the visceral motor system.
Epinephrine (EPI / Adrenaline): Epinephrine, also called adrenaline, is a catecholamine, but it is often considered a hormone instead of a neurotransmitter. Epinephrine is primarily released by the adrenal medulla into the circulation; it is used as a neurotransmitter in only a small number of neurons.
In the presynaptic terminal, the amino acid tyrosine is converted into DOPA via tyrosine hydroxylase, which is the rate-limiting step in the synthesis of all the catecholamines. DOPA is then converted to dopamine by DOPA decarboxylase. Dopamine is packaged into small synaptic vesicles by the vesicular monoamine transporter (VMAT).
The first step in catecholamine synthesis is catalyzed by tyrosine hydroxylase in a reaction requiring oxygen as a co-substrate and tetrahydrobiopterin as a cofactor to synthesize dihydroxyphenylalanine (DOPA). Because tyrosine hydroxylase is rate-limiting for the synthesis of all three transmitters, its presence is a valuable criterion for identifying catecholaminergic neurons.
In neurons that release norepinephrine, once dopamine is packaged into small synaptic vesicles, a membrane-bound enzyme called dopamine beta-hydroxylase converts dopamine into norepinephrine. In the adrenal medulla, norepinephrine is converted to epinephrine in a methylation step catalyzed by phenylethanol-N-methyl transferase; S-adenosylmethionine (SAM) is the methyl donor.
A cell that uses epinephrine as its transmitter contains four enzymes (TH, AADC, DBH, and PNMT), whereas norepinephrine neurons contain only three enzymes (lacking PNMT) and dopamine cells only two (TH and AADC).
The enzymes of the catecholamine biosynthetic pathway depend on several nutritional cofactors. Vitamins B6 and C are essential cofactors for the enzymes that convert amino acids into catecholamines like dopamine and norepinephrine. Folate is involved in the methylation reactions essential for catecholamine synthesis, and iron is needed as a cofactor for tyrosine hydroxylase activity.
Catecholamines can be degraded either by methylation by catechol-O-methyltransferases (COMT) or by deamination by monoamine oxidases (MAO). Catabolism of catecholamines is mediated by two main enzymes: catechol-O-methyltransferase (COMT) which is present in the synaptic cleft and cytosol of the cell, and monoamine oxidase (MAO) which is located in the mitochondrial membrane. Both enzymes require cofactors: COMT uses Mg²⁺ as a cofactor while MAO uses FAD.
Primary dopamine metabolite DOPAC is converted to homovanillic acid (HVA), which is the end-product of dopamine degradation. The primary end-product of norepinephrine and epinephrine catabolism is vanillylmandelic acid (VMA), which is excreted in the urine.
Mucuna pruriens, a plant traditionally used in Ayurvedic medicine, contains a significant amount of L-dopa (4%–6%), the primary active component of conventional levodopa (LD) therapy — the gold standard treatment for PD. Analytical studies of commercial Mucuna pruriens supplements have found quality variation: analysis revealed that L-DOPA levels were 66.2% to 82.7% of the values reported by manufacturers. Additionally, tyrosine and phenylalanine were present in both free and protein bound forms in all preparations analysed, potentially offering protection against the mistaken incorporation of L-DOPA into proteins and promoting increased dopamine synthesis.
Epinephrine and norepinephrine influence cells by binding to adrenergic receptors, a class of G protein-coupled receptors (GPCRs). These receptors are broadly categorized into 2 main types: α- and β-adrenergic receptors, each further classified into subtypes.
The key adrenergic receptor subtypes and their actions include:
Although dopamine primarily acts on dopamine receptors, it can also interact with adrenergic receptors, especially in peripheral tissues.
Activation of β-adrenergic receptors stimulates adenylyl cyclase, which generates cyclic AMP (cAMP) as a second messenger. The activation of this molecule results in the stimulation of cell-signaling pathways that act to increase heart rate, to dilate blood vessels in skeletal muscle, and to break down glycogen to glucose in the liver.
Dopamine (DA) and norepinephrine (NE) are catecholamines primarily studied in the central nervous system that also act in the pancreas as peripheral regulators of metabolism. Human and mouse pancreatic α- and β-cells express the catecholamine biosynthetic and signaling machinery, and α-cells synthesize DA de novo. This locally-produced pancreatic DA signals via both α- and β-cell adrenergic and dopaminergic receptors with different affinities to regulate glucagon and insulin release.
Once tyrosine has passed the blood-brain barrier and is taken up by the appropriate brain cells, it is converted into L-DOPA through an enzyme called tyrosine hydroxylase (TH). TH activity initially increases upon consumption of tyrosine, but it is regulated by end-product inhibition, preventing large increases in catecholamine release. This feedback mechanism is clinically important: it means dietary tyrosine supplementation is unlikely to cause pathological catecholamine excess in healthy individuals. Plasma tyrosine levels peak between 1 and 2 hours after consumption and can remain significantly elevated up to 8 hours.
In the cardiovascular system, epinephrine and norepinephrine increase cardiac output and blood pressure. Epinephrine is used in anaphylactic shock to stimulate both α- and β-receptors, leading to vasoconstriction, bronchodilation, and increased heart rate and cardiac output. Norepinephrine is a first-line vasopressor in septic shock, primarily stimulating α1-receptors to increase vascular tone and blood pressure while having less impact on heart rate than other agents. Dopamine causes vasodilation at low doses but stimulates β1- and α1-adrenergic receptors at higher doses, increasing cardiac output and blood pressure.
In the nervous system, dopamine influences mood, attention, and arousal. Dopamine is also crucial for the brain's reward system and motor control. As neurotransmitters and hormones, catecholamines play vital roles for the maintenance of body homeostasis through the autonomic nervous system.
In the endocrine system, epinephrine and norepinephrine influence the release of other hormones, such as insulin and glucagon, to regulate blood sugar levels.
In the respiratory system, epinephrine and norepinephrine dilate bronchioles and improve airflow.
In the musculoskeletal system, epinephrine increases blood flow to skeletal muscles.
Catecholamines maintain homeostasis by promptly responding to stressors. The acute release of epinephrine and norepinephrine in response to threat — often described as the "fight-or-flight" response — coordinates multiple organ systems simultaneously, mobilizing energy reserves, increasing alertness, and redirecting blood flow.
Note: This section reviews the evidence for supplementing with catecholamine precursors (primarily L-tyrosine and Mucuna pruriens/L-DOPA), as direct catecholamine ingestion is not a viable supplement strategy due to poor bioavailability and the blood-brain barrier.
Overview of evidence: This is the most extensively studied area in the context of catecholamine precursor supplementation. Consuming the amino acid tyrosine (TYR), the precursor of dopamine (DA) and norepinephrine (NE), may counteract decrements in neurotransmitter function and cognitive performance. However, reports on the effectiveness of TYR supplementation vary considerably, with some studies finding beneficial effects, whereas others do not.
Review findings: A systematic review of the cognitive and behavioral literature on tyrosine supplementation concluded that the potential of using TYR supplementation to treat clinical disorders seems limited and its benefits are likely determined by the presence and extent of impaired neurotransmitter function and synthesis. Likewise, the potential of TYR supplementation for enhancing physical exercise seems minimal as well, perhaps because the link between physical exercise and catecholamine function is mediated by many other factors.
Cold stress: One randomized controlled study (n=15) examined tyrosine's effects under cold-water immersion. Supplemental tyrosine is effective at limiting cold-induced decreases in working memory, presumably by augmenting brain catecholamine levels, since tyrosine is a precursor for catecholamine synthesis. Subjects ingested an energy bar during each trial; on one cold trial the bar contained tyrosine (300 mg/kg body weight). On placebo, performance on a Match-to-Sample task decreased 18% and marksmanship performance decreased 14%, compared to control, but there was no difference between the tyrosine group and control.
Reinforcement learning and decision-making: A double-blind, placebo-controlled, within-subject crossover study (n=28 healthy male participants) investigated a single 2 g dose of tyrosine versus placebo. On a physiological level, tyrosine intake reduced participants' arousal as revealed by increases in pupil dilation variability and reductions in heart rate compared with placebo. With respect to task performance, participants' response times decreased consistently in both tasks without deteriorating task performance. Hierarchical drift diffusion modeling linked this with attenuated decision-thresholds in both tasks. The authors themselves noted that supplementation with the catecholamine precursor L-Tyrosine might enhance cognitive performance, but overall findings are mixed.
Broader cognitive domains: In addition to counteracting decrements of cognitive performance in working memory tasks, a few studies indicated that a single dose of tyrosine administration may improve a wider range of cognitive functions, including cognitive flexibility, inhibitory control, working memory, and reasoning. There is also evidence for positive effects of long-term tyrosine intake on cognitive performance, reflected in associations between daily tyrosine intake and working memory, episodic memory, and fluid intelligence.
Heat stress: In contrast, a double-blind crossover study in military-based protocols found that despite marked elevations in serum tyrosine concentration, ingestion of tyrosine did not influence cognitive function or physical performance during exercise heat stress.
Evidence strength: Overall, the human evidence for tyrosine supplementation improving cognition is preliminary and inconsistent. Benefits appear most likely when baseline catecholamine synthesis is acutely depleted by stressors such as cold, sleep deprivation, or extreme cognitive demand. The evidence does not support universal cognitive enhancement in non-stressed individuals.
Overview: Parkinson disease is a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the substantia nigra. The resulting dopamine deficiency disrupts the balance between excitatory and inhibitory pathways in the basal ganglia, leading to the classic motor symptoms of tremor, rigidity, bradykinesia, and postural instability. Because L-DOPA (levodopa) is used to treat Parkinson's disease (PD), a condition in which the progressive loss of dopaminergic neurons causes dopamine deficiency and impaired motor function, and because Mucuna pruriens contains natural L-DOPA, it has attracted clinical interest as a complementary therapy.
Systematic review (2025): A systematic review searching PubMed, Embase, and Web of Science identified 5 clinical trials totaling 108 participants (mean age 60 years). Out of 466 articles identified, 5 clinical trials involving a total of 108 participants (mean age: 60 years) were included. Quality assessment rated one study as high quality, one as having some concerns, and three as low quality. Despite heterogeneity in M. pruriens interventions, the findings consistently showed improvements in PD symptoms and therapy-related complications. Treatment with M. pruriens was associated with a shorter time to reach the "on" disease stage, prolonged duration of this stage, and fewer adverse events, with no dyskinesia reported. The reviewers concluded that M. pruriens shows promise in improving motor symptoms and reducing therapy complications in PD patients. However, current clinical evidence is limited, and further high-quality trials are needed to confirm its efficacy and safety.
Double-blind crossover trial: A randomized, controlled, double-blind crossover trial involving eight Parkinson's disease patients challenged participants with single doses of 200/50 mg levodopa/carbidopa, and 15 and 30 g of mucuna preparation in randomised order at weekly intervals. Mucuna preparations demonstrated L-DOPA pharmacokinetics that were faster-onset and with a longer duration of "on" state compared to standard levodopa/carbidopa.
Ayurvedic review: A narrative review of Ayurvedic interventions for PD (clinical trials from 2000 to 2020) found that among the seven included studies, six showed the beneficial effects of M. pruriens, either as a stand-alone or in combination with other herbs, and one trial highlighted the significance of bio-cleansing along with M. pruriens. Duration of intervention ranged from assessment of acute effects to 56 weeks. The synthesis of the reviewed data showed that M. pruriens exhibited an extended ON state, effectively ameliorating motor symptoms even among individuals afflicted with advanced PD while manifesting a favourable side effect profile.
Additional properties: M. pruriens is also recognized for its anti-inflammatory, antioxidant, antiapoptotic, and antiparkinsonian properties, which collectively suggest therapeutic benefits for individuals with PD.
Evidence strength: Evidence is preliminary but consistently positive in small trials. Most studies are small, heterogeneous, and of variable quality. High-quality, large randomized controlled trials are lacking.
The potential of TYR supplementation for enhancing physical exercise seems minimal, perhaps because the link between physical exercise and catecholamine function is mediated by many other factors. Conversely, exercise itself is a potent modulator of catecholamine signaling. The alterations in autonomic outflow during exercise evoke changes in cardiac and vascular function, as well as release of catecholamines from the adrenal medulla.
In the context of Parkinson's disease, exercise has attracted interest as a means of supporting dopaminergic integrity. A study using PET imaging evaluated the dopaminergic system in mild and early PD patients before and after six months of intense exercise. Exercise reversed the expected decrease in DAT availability into a significant increase in both the substantia nigra and putamen. Exercise also reversed the expected decrease in neuromelanin concentration in the substantia nigra into a significant increase. These findings suggest improved functionality in the remaining dopaminergic neurons after exercise.
While pharmaceutical use of catecholamines falls outside the dietary supplement domain, it provides important context. The synthetic equivalents of catecholamines are often administered in septic shock to counteract vasoplegia and/or myocardial depression. Epinephrine was the first hormone to be successfully isolated and has been used in the treatment of anaphylaxis since the turn of the 20th century.
Most trials that investigated the effects of Mucuna pruriens on symptoms of Parkinson's disease or male infertility have used daily doses ranging between 5 and 45 grams of adequately prepared seed powder, corresponding to approximately 200 mg to 1,500 mg of L-DOPA. Research in male fertility contexts has explored the ability of dopamine-precursor compounds to modulate gonadotropin release and spermatogenesis, though the evidence base for this application remains preliminary and primarily derives from small studies.
In nutritional science, catecholamine precursors like tyrosine and phenylalanine have been explored for their potential to support cognitive function, mental alertness, and physical performance. Because dopamine and norepinephrine are well-established modulators of mood and motivation, their precursors have been investigated for potential antidepressant effects. However, the potential of using TYR supplementation to treat clinical disorders seems limited and its benefits are likely determined by the presence and extent of impaired neurotransmitter function and synthesis. Clinical evidence for precursor loading as an antidepressant strategy remains weak and inconsistent in human trials.
Dysregulation of catecholamine production or signaling can disrupt essential processes, contributing to disorders such as hypertension, heart failure, anxiety, and neurodegenerative diseases. The major catecholamine-related pathological conditions include:
Testing for catecholamine levels and their metabolites is crucial in diagnosing and managing various medical conditions, including autonomic nervous system and adrenal dysfunction, as well as neuroendocrine tumors. Plasma and urinary catecholamine measurements are commonly used to assess the levels of dopamine, norepinephrine, and epinephrine.
Catecholamines are rapidly inactivated by the enzyme catechol-O-methyltransferase, producing metanephrine and normetanephrine, which are subsequently conjugated with sulfate. These metabolites have a longer half-life and are excreted in the urine, making them more suitable for measurement than catecholamines. Elevated levels of catecholamines or their metabolites, such as metanephrine and vanillylmandelic acid (VMA), are indicative of these conditions.
Mucuna pruriens naturally contains levodopa (a prescription medication), but there are quality concerns in some products. Some products contained either no levodopa or drastically varying amounts, from 2 to 241 mg per serving.
Mucuna pruriens should not be used in conjunction with medications that contain L-DOPA; combining the two could potentially result in excessively high dopamine levels, leading to adverse effects.
Mucuna pruriens has a well-established and potentially dangerous interaction with MAO inhibitors: as a direct source of L-dopa, combined use can dramatically potentiate dopamine signaling, causing severe hypertension and autonomic instability.
Direct contact with Mucuna pruriens pods can cause severe itching and rashes, and consuming raw beans and seeds may cause poisoning and toxicity. Supplementation should be avoided during pregnancy and breastfeeding because safety evidence is limited.
Because it contains levodopa, Mucuna pruriens may have similar drug interactions to levodopa, though limited research on Mucuna pruriens itself suggests that the exact implications of these interactions are unknown.
In Parkinson's disease treatment, it is known that L-DOPA can decrease blood pressure and aggravate orthostatic hypotension as a result of a negative inotropic effect on the heart. This unwanted side effect limits the therapeutic use of L-DOPA in geriatric patients with PD and can contribute to the number of hospital admissions.
L-tyrosine carries a theoretical MAOI risk; tyrosine can be decarboxylated to tyramine in the gut, and tyramine causes hypertensive crisis when MAO-mediated breakdown is blocked, but no clinical cases of hypertensive crisis from supplemental L-tyrosine plus a MAOI have been documented. Both supplements should be avoided with MAO inhibitors until further evidence is available.
Supplemental dopamine precursors should be avoided in pheochromocytoma, a rare tumor that secretes catecholamines.
Dysregulation of catecholamine production or signaling can disrupt essential processes, contributing to disorders such as hypertension, heart failure, anxiety, and neurodegenerative diseases. In the case of pheochromocytoma, mechanical factors such as abdominal palpation, sexual intercourse, coughing, sneezing, defecation, pain, extreme emotions, and exposure to cold can trigger hypertensive crises in otherwise asymptomatic catecholamine-secreting tumors.
For dietary tyrosine supplementation, the body's feedback regulation provides an important safety buffer. TH activity initially increases upon consumption of tyrosine, but it is regulated by end-product inhibition, preventing large increases in catecholamine release. This mechanism sharply distinguishes the pharmacological effects of precursor supplementation from the effects of exogenous catecholamine administration.
Given that catecholamine precursors increase dopamine and norepinephrine synthesis, their use alongside medications that modulate monoamine signaling — such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, SNRIs, or antipsychotics — carries theoretical pharmacodynamic interaction risks. MAOIs bind to MAO, thereby preventing it from breaking down catecholamines and other monoamines, which means coadministration with catecholamine precursors could elevate neurotransmitter levels unpredictably.
Health conditions that Catecholamine may help support.
Body systems that Catecholamine may help support.
Go back